Brought to you by 
Pharmasset, Roche enter hepatitis C agreement
02 Nov 2004
Executive Summary
Antiviral drug development company Pharmasset licensed F. Hoffman-La Roche worldwide rights (except in Latin America and Korea) to develop the nucleoside polymerase inhibitor PSI-6130 and its prodrugs for hepatitis C virus (HCV).
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com